Long-term efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis who had failed or were intolerant to oral nonsteroidal immunosuppressants: pooled analysis of JADE clinical trials

被引：0

作者：

Ardern-Jones, M. ^{[1
]}

Ameen, M. ^{[2
]}

de Bruin-Weller, M. ^{[3
]}

Simpson, E. ^{[4
]}

Chiu, W. S. ^{[5
]}

Biswas, P. ^{[6
]}

Chan, G. ^{[7
]}

Koulias, C. ^{[8
]}

Weidinger, S. ^{[9
]}

机构：

[1] Univ Southampton, Southampton Gen Hosp, Southampton, Hants, England

[2] Royal Free London Natl Hlth Serv Fdn Trust, London, England

[3] Univ Med Ctr Utrecht, Utrecht, Netherlands

[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[5] Pfizer Ltd, Surrey, England

[6] Pfizer Inc, New York, NY USA

[7] Pfizer Inc, Groton, CT 06340 USA

[8] Pfizer Hellas SA, Athens, Greece

[9] Univ Hosp Schleswig Holstein, Kiel, Germany

来源：

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

642

引用

页码：E151 / E152

页数：2